to Press Release List
Advanced Renal Technologies
BELLEVUE, Wash., USA – Advanced
Renal Technologies (“ART”), developers of Citrasate®
and DRYalysate® citric acid-based dialysate concentrates,
announced today they will have exhibit booth D14 at NephroAsia,
February 9-12, 2004 in Singapore. “ART is excited
to be a part of Asia’s premier nephrology meeting,”
said Mike Fulton, managing director of ART, based in Bellevue,
Washington (USA). “As a developer of innovative technologies,
ART relies on international meetings such as NephroAsia
to make important contacts to partner with high quality
manufacturers, distributors and academic partners throughout
Citrasate and DRYalysate are patented
acid concentrates using citric acid, a known anticoagulant.
ART’s citric acid-based dialysate concentrates are
particularly helpful in better dialysis for those patients
where heparin is contraindicated, such as heparin antibodies
or allergies. The acid concentrate products are also helpful
in acute dialysis where there is a risk of bleeding or clotting.
Citrasate and DRYalysate have been shown to prevent dialyzer
clotting, reduce metabolic acidosis and increase reuse of
Advanced Renal Technologies, Inc.
is a privately held company focused on the development of
products to improve the treatment of patients with acute
and chronic kidney failure. More information about Advanced
Renal Technologies, Inc. and its dialysate products may
be found at www.citrasate.com.